利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.021 秒)

    DISEASE RISK FACTORS AND METHODS OF USE
    1.
    发明申请
    DISEASE RISK FACTORS AND METHODS OF USE 审中-公开

    公开(公告)号：US20190032137A1

    公开(公告)日：2019-01-31

    申请号：US16031218

    申请日：2018-07-10

    申请人： Zinfandel Pharmaceuticals, Inc.

    发明人： Allen D. Roses

    IPC分类号： C12Q1/6883 ,  A61K31/4439

    摘要： Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene.

    Methods for detecting structural variants in neurodegenerative disease
    3.
    发明授权
    Methods for detecting structural variants in neurodegenerative disease 有权

    公开(公告)号：US11001893B2

    公开(公告)日：2021-05-11

    申请号：US16308315

    申请日：2017-06-09

    申请人： Zinfandel Pharmaceuticals, Inc. ,  Ann M. Saunders

    发明人： Allen D. Roses

    IPC分类号： C12Q1/68 ,  C12P19/34 ,  C12Q1/6883

    摘要： Provided herein according to some embodiments is a method for detecting a short tandem repeat (STR) variant in the SOD1, TARDBP or C9orf72 gene region comprising measuring the length of the STR variant. In some embodiments, the method V includes obtaining a biological sample containing genomic DNA from a subject, optionally isolating the genomic DNA from the sample. Also provided is a method for determining a diagnosis or a prognosis for a neurodegenerative disease, including: measuring a length of a short tandem repeat (STR) variant in the SOD1, TARDBP or C9orf72 gene region, and determining the diagnosis or prognosis based upon the length. Further provided is a method of treatment for a neurodegenerative disease including: administering a therapeutic agent to a subject based upon a length of a short tandem repeat (STR) variant in the SOD1, TARDBP or C9orf72 gene region in the subject. Also provided is a kit for detecting a (STR) variant in the SOD1, TARDBP or C9orf72 gene region.

    Method of identifying disease risk factors
    4.
    发明授权
    Method of identifying disease risk factors 有权
    识别疾病危险因素的方法

    公开(公告)号：US08815508B2

    公开(公告)日：2014-08-26

    申请号：US13058724

    申请日：2009-08-11

    申请人： Allen D. Roses

    发明人： Allen D. Roses

    IPC分类号： C12Q1/68 ,  C12P19/34

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided.

    摘要翻译： 本文提供了用于鉴定与兴趣条件（例如阿尔茨海默病）的发展相关的遗传变异体和如此鉴定的遗传变异体的方法。 在检测本文所述的遗传变体时，还提供了用活性剂（例如，与特定活性剂和/或较早年龄）一起治疗的方法。 在一些实施方案中，遗传变体是TOMM40基因的缺失/插入多态性（DIP）。 还提供了用于确定受试者是否处于发病晚期阿尔茨海默氏病的风险增加的试剂盒。 进一步提供用于确定受试者是否对活性成分感兴趣的病症的治疗有反应的试剂盒。

    DISEASE RISK FACTORS AND METHODS OF USE
    6.
    发明申请
    DISEASE RISK FACTORS AND METHODS OF USE 审中-公开
    疾病风险因素及使用方法

    公开(公告)号：US20150073022A1

    公开(公告)日：2015-03-12

    申请号：US14464961

    申请日：2014-08-21

    申请人： Zinfandel Pharmaceuticals, Inc.

    发明人： Allen D. Roses

    IPC分类号： C12Q1/68 ,  A61K31/4439

    CPC分类号： C12Q1/6883 ,  A61K31/4439 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

    摘要： Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene.

    摘要翻译： 本文提供与感兴趣的疾病的发展相关的遗传变异（例如，阿尔茨海默病）。 在检测本文所述的遗传变体时，还提供了用活性剂（例如，与特定活性剂和/或较早年龄）一起治疗的方法。 在一些实施方案中，遗传变体是TOMM40基因的缺失/插入多态性（DIP）。

    Disease risk factors and methods of use
    7.
    发明授权
    Disease risk factors and methods of use 有权
    疾病风险因素及使用方法

    公开(公告)号：US08846315B2

    公开(公告)日：2014-09-30

    申请号：US13029713

    申请日：2011-02-17

    申请人： Allen D. Roses

    发明人： Allen D. Roses

    IPC分类号： C12Q1/68 ,  C12P19/34 ,  A61P25/28 ,  A61K31/4439

    CPC分类号： C12Q1/6883 ,  A61K31/4439 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

    摘要： Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene.

    摘要翻译： 本文提供与感兴趣的疾病的发展相关的遗传变异（例如，阿尔茨海默病）。 在检测本文所述的遗传变体时，还提供了用活性剂（例如，与特定活性剂和/或较早年龄）一起治疗的方法。 在一些实施方案中，遗传变体是TOMM40基因的缺失/插入多态性（DIP）。

    METHOD OF IDENTIFYING DISEASE RISK FACTORS
    8.
    发明申请
    METHOD OF IDENTIFYING DISEASE RISK FACTORS 有权

    公开(公告)号：US20210095345A1

    公开(公告)日：2021-04-01

    申请号：US17097705

    申请日：2020-11-13

    申请人： Zinfandel Pharmaceuticals, Inc.

    发明人： Allen D. Roses

    IPC分类号： C12Q1/6883

    摘要： Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided.